LIN vs OGEN · P/E 34, rev $33.99B vs rev $37.7K
Linde plc Ordinary Shares (LIN) versus Oragenics Inc (OGEN) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Oragenics Inc (OGEN) is a biotechnology company listed on US.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Latest reported OGEN revenue for 2023-12-31 was $37.7K. Net income was -$20.7M. Revenue was down 71.4% from 2022-12-31 to 2023-12-31. OGEN currently screens at market cap $2.7M.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. OGEN currently screens at market cap $2.7M.
Not investment advice. Open the LIN and OGEN stock pages for the full models.
Not investment advice.